As innovative new drugs flow from China, some see an opportunity, others a threat.

The pandemic led to an explosion of interest in and funding of biotech. That continues even as many sectors slow and recession fears grow.

The free market is pretty simple: There’s supply, there’s demand, they meet somewhere in the middle. If there’s a need, there’s a product. But sometimes, that system breaks down, as it has in the market for antibiotics.

In her new co-authored book, “The Genesis Machine,” futurist Amy Webb walks readers through an imagined reproductive technology center.

Pricing on the open market is opaque, one expert says. Ultimately, the cost is anyone’s guess.

It's become a cautionary tale for biotech investors. Are they heeding it?